Expanding the patient population will determine any capacity for TNF-antagonists to reduce surgical endpoints for BPH as well as discern if there are associations with AI disease treatment and BPH diagnoses across racial and ethnic groups. Here, TNF is linked to benign prostatic hyperplasia.